Ignite Creation Date:
2025-12-24 @ 6:51 PM
Ignite Modification Date:
2026-01-05 @ 6:23 PM
Study NCT ID:
NCT03836157
Status:
WITHDRAWN
Last Update Posted:
2019-06-27
First Post:
2019-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
Sponsor:
University of Oklahoma
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-05-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2021-11-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-05
Completion Date Type:
ESTIMATED
First Submit Date:
2019-02-07
First Submit QC Date:
None
Study First Post Date:
2019-02-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-06-25
Last Update Post Date:
2019-06-27
Last Update Post Date Type:
ACTUAL